Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

Affiliations

¹ Clinique medicale l'Actuel, Montreal, QC, Canada.
² UCLA Clinical AIDS Research and Education Center, University of California, Los Angeles, CA, USA.
³ CascAIDS Research, Toronto, ON, Canada.
⁴ Central Texas Clinical Research, Austin, TX, USA.
⁵ Hope Clinical Research, San Juan, Puerto Rico.
⁶ ViiV Healthcare, Research Triangle Park, NC, USA.
⁷ ViiV Healthcare, Collegeville, PA, USA.
⁸ GlaxoSmithKline, Stockley Park, UK.
⁹ ViiV Healthcare, Brentford, UK.

Published Erratum

Benoît Trottier et al. Antivir Ther. 2017.

. 2017;22(5):459-460.

doi: 10.3851/IMP3192. Epub 2017 Sep 13.

¹ Clinique medicale l'Actuel, Montreal, QC, Canada.
² UCLA Clinical AIDS Research and Education Center, University of California, Los Angeles, CA, USA.
³ CascAIDS Research, Toronto, ON, Canada.
⁴ Central Texas Clinical Research, Austin, TX, USA.
⁵ Hope Clinical Research, San Juan, Puerto Rico.
⁶ ViiV Healthcare, Research Triangle Park, NC, USA.
⁷ ViiV Healthcare, Collegeville, PA, USA.
⁸ GlaxoSmithKline, Stockley Park, UK.
⁹ ViiV Healthcare, Brentford, UK.

No abstract available

Erratum for

Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Trottier B, Lake JE, Logue K, Brinson C, Santiago L, Brennan C, Koteff JA, Wynne B, Hopking J, Granier C, Aboud M. Trottier B, et al. Antivir Ther. 2017;22(4):295-305. doi: 10.3851/IMP3166. Epub 2017 Apr 12. Antivir Ther. 2017. PMID: 28401876 Clinical Trial.